Dr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...

UTUC is a rare malignancy, primarily affecting older men, with smoking as a significant risk factor. Nephron-sparing approaches are gaining interest due to complications from nephroureterectomy and ...

Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the ...

Adding immunotherapy to platinum chemotherapy can improve outcomes of urothelial carcinoma, but that may depend on the platinum agent used.

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Urogen Pharma (URGN – Research Report), with a ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Urogen Pharma (URGN – Research Report). The ...

On October 10, 2024, Boxer Capital, LLC made a significant addition to its investment portfolio by acquiring 85,939 shares of Tyra Biosciences Inc (NASDAQ:TYRA). This transaction has increased the ...

Researchers discovered that antiviral enzymes induce early mutations in bladder cancer, and standard chemotherapy causes ...

The study focused on urothelial carcinoma, the most common form of bladder cancer, and used advanced whole-genome sequencing ...